Supreme Court Ruling: Gene Patent Compromise

Thursday, June 13, 2013

The Supreme Court unanimously ruled today that naturally occurring human genes can not be patented. All nine justices agreed that while naturally occurring D.N.A. cannot be patented, synthetic D.N.A. can. The case at hand involves Myriad Genetics, the company that patented the BCRA-1 and BCRA-2 genes, which indicate an increased risk for breast and ovarian cancer.

The court's decision is considered a significant victory for cancer patients whose medication and treatment costs might go down as a result of this decision.

Robert Blackburn is a former Vice President and Chief Patent Counsel of Chiron Corporation, an American multinational biotechnology firm.


Robert Blackburn

Leave a Comment

Register for your own account so you can vote on comments, save your favorites, and more. Learn more.
Please stay on topic, be civil, and be brief.
Email addresses are never displayed, but they are required to confirm your comments. Names are displayed with all comments. We reserve the right to edit any comments posted on this site. Please read the Comment Guidelines before posting. By leaving a comment, you agree to New York Public Radio's Privacy Policy and Terms Of Use.